Leavell Investment Management Inc. Sells 540 Shares of Becton Dickinson and Co (BDX)
Leavell Investment Management Inc. reduced its position in Becton Dickinson and Co (NYSE:BDX) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,614 shares of the medical instruments supplier’s stock after selling 540 shares during the quarter. Leavell Investment Management Inc.’s holdings in Becton Dickinson and were worth $3,342,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Waverton Investment Management Ltd increased its stake in shares of Becton Dickinson and by 9.0% in the 4th quarter. Waverton Investment Management Ltd now owns 432,388 shares of the medical instruments supplier’s stock worth $92,557,000 after acquiring an additional 35,776 shares during the last quarter. Neville Rodie & Shaw Inc. acquired a new stake in shares of Becton Dickinson and in the 4th quarter worth $318,000. Atlantic Trust Group LLC increased its stake in shares of Becton Dickinson and by 597.3% in the 3rd quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock worth $88,381,000 after acquiring an additional 386,349 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Becton Dickinson and by 3.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,343,797 shares of the medical instruments supplier’s stock worth $263,317,000 after acquiring an additional 43,396 shares during the last quarter. Finally, AXA increased its stake in shares of Becton Dickinson and by 8.4% in the 3rd quarter. AXA now owns 518,636 shares of the medical instruments supplier’s stock worth $101,627,000 after acquiring an additional 40,370 shares during the last quarter. 75.53% of the stock is owned by institutional investors and hedge funds.
A number of analysts have issued reports on BDX shares. Royal Bank of Canada reaffirmed a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Morgan Stanley raised their target price on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Wells Fargo & Co started coverage on Becton Dickinson and in a research note on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price for the company. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $230.20.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.12 EPS. analysts expect that Becton Dickinson and Co will post 10.89 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were issued a dividend of $0.75 per share. The ex-dividend date was Thursday, December 7th. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. Becton Dickinson and’s dividend payout ratio is currently 64.52%.
COPYRIGHT VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/11/leavell-investment-management-inc-sells-540-shares-of-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.